一分钟看懂
这是一项关于Malignancy, Hematologic的I 期研究，登记的药物或干预包括aldesleukin；cyclophosphamide；fludarabine phosphate；Individual Patient TCR-Transduced PBL；TruSight Oncology (TSO) 500，当前状态为招募中。登记地点显示中国Bethesda有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
aldesleukin；cyclophosphamide；fludarabine phosphate；Individual Patient TCR-Transduced PBL；TruSight Oncology (TSO) 500 · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Institutes of Health Clinical Center · Bethesda
公开的入选条件
- Malignancy diagnosis requirements:
- -Eligible diagnoses include AML (acute myeloid leukemia), MDS (myelodysplastic syndrome), CMML(chronic myelomonocytic leukemia), CML (chronic myeloid leukemia), and T-ALL (T-acute lymphoblastic leukemia/lymphoma) meeting standard diagnostic criteria as describ
- NOTE: Pathology reports are acceptable to confirm eligibility.
- Malignancy mutation and HLA requirements:
- * Detection of at least one of the neoepitope-forming TP53 or RAS mutations that are listed in Table 3 in on the TruSight Oncology (TSO) 500 sequencing panel (NSR device) performed in the NCI Laboratory of Pathology is required. RAS mutations can be in NRAS, K
- * Presence of the correct HLA type needed to present one of the targeted neoepitopes as shown in Table 3. HLA typing data from any time-point prior to apheresis can be used to meet this requirement.
- Table 3: Eligibility requirements for the targeted mutation and HLA type
- Targeted mutation
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06904066；登记信息更新于 2026-09-17。